ZANTE GREG
SEC CIK 1264949 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VKTX | Viking Therapeutics, Inc. | CFO | 212.2K | — | $26.05M | 37 | 2021-09-28 | 2026-07-29 |
Most active insiders at VKTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lian Brian | Pres, CEO, Dir | — | $14.01M |
| 2 | ZANTE GREG | CFO | — | $2.82M |
| 3 | Mancini Marianna | COO | — | $2.73M |
| 4 | Rowland Charles A Jr | Dir | — | $2.13M |
| 5 | FOEHR MATTHEW W | Dir | — | $561.8K |
| 6 | Aubuchon Neil William | Chief Commercial Off | $149.9K | — |
| 7 | Kelly-Gemmell Dorothy Elizabeth | Dir | — | — |
| 8 | Rouan Sarah Kathryn | Dir | — | — |
| 9 | MACARTNEY LAWSON | Dir | — | — |
| 10 | SINGLETON J MATTHEW | Dir | — | — |
Transactions 37
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 20:06 | 2026-07-28 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +31.7K | 233.4K | +16% | $0 | |
| 2026-07-29 20:06 | 2026-07-29 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale | $33.47 | -21.2K | 212.2K | -9% | -$710.1K | |
| DM | 2026-01-05 | 2026-01-02 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +73.0K | 247.5K | +42% | $0 |
| DM | 2026-01-05 | 2026-01-05 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale | $32.90 | -57.7K | 189.9K | -23% | -$1.90M |
| 2025-10-28 | 2025-10-28 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale | $35.00 | -6,185 | 173.6K | -3% | -$216.5K | |
| 2025-10-28 | 2025-10-27 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +11.1K | 179.8K | +7% | $0 | |
| 2025-07-03 | 2025-07-03 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale | $27.76 | -4,266 | 168.7K | -2% | -$118.4K | |
| 2025-07-03 | 2025-07-02 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +7,667 | 172.9K | +5% | $0 | |
| DM | 2025-01-06 | 2025-01-03 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +66.2K | 215.6K | +44% | $0 |
| DM | 2025-01-06 | 2025-01-06 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale | $42.75 | -50.3K | 170.0K | -23% | -$2.15M |
| DMT | 2024-10-28 | 2024-10-28 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | M - OptEx | $7.49 | +94.0K | 199.8K | +89% | +$704.3K |
| DMT | 2024-10-28 | 2024-10-28 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale+OE | $76.62 | -131.7K | 158.5K | -45% | -$10.09M |
| M | 2024-07-31 | 2024-07-29 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +28.3K | 181.5K | +18% | $0 |
| M | 2024-07-31 | 2024-07-30 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale | $57.15 | -16.1K | 187.1K | -8% | -$922.2K |
| DM | 2024-05-03 | 2024-05-03 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | M - OptEx | $4.86 | +34.2K | 211.6K | +19% | +$166.3K |
| DM | 2024-05-03 | 2024-05-03 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale+OE | $74.69 | -66.8K | 192.9K | -26% | -$4.99M |
| 2024-03-27 | 2024-03-27 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | F - Tax | $83.34 | -16.6K | 207.4K | -7% | -$1.38M | |
| 2024-03-27 | 2024-03-27 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +31.7K | 224.0K | +16% | $0 | |
| 2024-03-04 | 2024-03-01 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | F - Tax | $85.22 | -20.1K | 192.3K | -9% | -$1.71M | |
| 2024-03-04 | 2024-03-01 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +31.7K | 212.4K | +18% | $0 | |
| DM | 2024-01-04 | 2024-01-03 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +98.3K | 188.7K | +109% | $0 |
| D | 2024-01-04 | 2024-01-04 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale | $17.90 | -15.0K | 180.7K | -8% | -$268.5K |
| DM | 2024-01-04 | 2024-01-03+ | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | F - Tax | $17.66 | -63.0K | 209.6K | -23% | -$1.11M |
| D | 2023-04-18 | 2023-04-17 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale+OE | $20.00 | -7,500 | 149.3K | -5% | -$150.0K |
| D | 2023-04-18 | 2023-04-17 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | M - OptEx | $13.07 | +7,500 | 156.8K | +5% | +$98.0K |
| DM | 2023-04-13 | 2023-04-11+ | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | M - OptEx | $5.57 | +97.8K | 152.5K | +179% | +$544.8K |
| DM | 2023-04-13 | 2023-04-11+ | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale+OE | $18.00 | -97.8K | 149.3K | -40% | -$1.76M |
| DM | 2023-04-03 | 2023-03-30+ | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | M - OptEx | $7.41 | +124.7K | 178.7K | +231% | +$923.7K |
| DM | 2023-04-03 | 2023-03-30+ | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | S - Sale+OE | $17.19 | -161.9K | 147.8K | -52% | -$2.78M |
| D | 2023-04-03 | 2023-04-03 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +56.7K | 204.4K | +38% | $0 |
| D | 2023-04-03 | 2023-04-03 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | F - Tax | $17.57 | -55.2K | 149.3K | -27% | -$969.3K |
| DM | 2023-01-04 | 2022-12-30+ | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +110.9K | 229.7K | +93% | $0 |
| DM | 2023-01-04 | 2022-12-30+ | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | F - Tax | $8.76 | -64.3K | 185.1K | -26% | -$563.4K |
| DM | 2022-01-05 | 2022-01-03+ | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | F - Tax | $4.69 | -11.9K | 136.3K | -8% | -$55.9K |
| D | 2022-01-05 | 2022-01-03 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +53.3K | 145.1K | +58% | $0 |
| 2021-09-30 | 2021-09-28 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | A - Grant | $0.00 | +6,667 | 96.8K | +7% | $0 | |
| 2021-09-30 | 2021-09-28 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | CFO | F - Tax | $6.50 | -2,306 | 94.5K | -2% | -$15.0K |
Purchase Sale Sale after option exercise All abbreviations